Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01661712
Other study ID # SOSATS2012-V1.0-01/08/2012
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 2013
Est. completion date December 2015

Study information

Verified date November 2018
Source Guy's and St Thomas' NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this randomized, double-blinded, sham-controlled cross-over trial is to demonstrate the effectiveness of continuous transcutaneous electrical stimulation of the pharyngeal dilator muscles to reduce sleep-disordered breathing.


Description:

Obstructive sleep apnoea is the most common problem of sleep-disordered breathing. It affects at least four percent of the male and two percent of the female adult population. It is associated with excessive daytime sleepiness, causing significant disturbance of daytime routines affecting work, social life and memory; untreated, it also causes a significant cardiovascular and metabolic risk. The best available treatment for obstructive sleep apnoea is continuous positive airway pressure (CPAP). However, not everyone eligible tolerates this treatment because it requires them to sleep with a nasal or full-face mask that is connected by a tube to a machine. Although CPAP is recommended by the National Institute for Health and Clinical Excellence (NICE) for moderate-severe sleep apnoea, approximately one third of sleep apnoea patients who should be on CPAP stop therapy within five years. Mild sleep apnoea is currently treated with mandibular advancement splints and generic sleep hygiene advice.

Continuous transcutaneous electrical stimulation (CTES) of the submental region activates the muscles that dilate the upper airway. This is where airway obstruction occurs in sleep apnoea. It has been shown that CTES at night for short periods (10minutes) effectively stimulates the genioglossus muscle, the strongest pharyngeal dilator and reduces upper airway obstruction, work of breathing and neural respiratory drive in patients with sleep apnoea. The London Respiratory Muscle Groups, based within King`s Health Partners and the Royal Brompton Hospital, has developed a CTES stimulator device. This device senses apnoeas and snoring and delivers CTES until normal ventilation has been restored.

We propose to undertake a randomized, double-blinded, sham-controlled cross-over trial with sleep apnoea patients to evaluate the efficacy of this method. Patients will be randomly assigned to a night of CTES or sham-stimulation. The primary outcome measure is the number of oxygen desaturations per hour (ODI) caused by apnoeas and the secondary outcome measures are sleepiness, as measured by the Epworth sleepiness score, the apnoea-hypopnoea-index (AHI) and comfort, as assessed by a visual analogue score. The sample size Calculation using data from our own published pilot study revealed that this study would require 44 patients to be enroled. The mean study duration until all outcomes will be assessed for each patient will be four weeks. We plan to commence the study in winter 2012/13 for a period of two years, including analysis and publication, to be concluded in December 2014.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- males and females, age >18years and <75years, body-mass index (BMI) >18 and <40kg/m2, non-smokers, sleep apnoea with an ODI =15/h or sleep apnoea with an ODI =5/h plus an Epworth sleepiness score >10.

Exclusion Criteria:

- morbid obesity (BMI>40kg/m2) or cachexia (BMI<18kg/m2), obesity-hypoventilation syndrome (total sleep time with oxygen saturation (SpO2) less than 90% of more than 10% of the night), active smokers or smoking history of >20pack years, acute or critical illness, acute psychosis or chronic mental disorder affecting capacity, previous home-mechanical non-invasive ventilation and metal implants in the upper part of the body (this excludes dental implants).

Study Design


Intervention

Device:
Transcutaneous electrical stimulation
Transcutaneous electrical stimulation (one night of electrical current titrated according to skin sensation)
Sham stimulation
Sham stimulation for one night (no electrical stimulation)

Locations

Country Name City State
United Kingdom Guy´s & St Thomas´ NHS Foundation Trust London

Sponsors (1)

Lead Sponsor Collaborator
Guy's and St Thomas' NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Steier J, Seymour J, Rafferty GF, Jolley CJ, Solomon E, Luo Y, Man WD, Polkey MI, Moxham J. Continuous transcutaneous submental electrical stimulation in obstructive sleep apnea: a feasibility study. Chest. 2011 Oct;140(4):998-1007. doi: 10.1378/chest.10- — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 4% Oxygen Desaturation Index (ODI, 4%) The primary outcome measure for this trial is the 4% oxygen desaturation index (ODI, 4%) per hour of sleep (h-1). The 4% ODI was chosen as primary outcome parameter over the AHI because an incomplete re-opening of the upper airway during an ongoing apnoeic effort caused by transcutaneous electrical stimulation (CTES) may result in a nominal increase of the AHI. We consider that the 4% ODI would be a more robust marker for the severity of sleep apnoea, low average oxygen levels indicating obesity-hypoventilation syndrome which will be an exclusion criterion.
Although a specific cut off is not well defined a 4% ODI =5 represent mild OSA whilst a 4% ODI =15 represents moderate-severe OSA. Normal range is usually considered 0-5 events/hour.
1st sleep study compared to 2nd sleep study (randomised order of intervention/sham or sham/intervention)
Secondary Apnoea-Hypopnoea Index (AHI) The Apnoea-Hypopnoea Index (AHI) is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. An apnea (pause in breathing) is defined by a temporary cessation of breathing that must last for at least 10 seconds and be associated with a decrease in blood oxygenation. A hypopnoea is a reduction of ventilation (shallow breathing) but not a complete cessation of breathing, lasting al least 10 seconds and associated with a decrease in blood oxygenation. 1st sleep study compared to 2nd sleep study (randomised order of intervention/sham or sham/intervention)
Secondary Nadir Oxygenation The nadir oxygenation (lowest SpO2, %) during the sleep study is measured while the patients are asleep. 1st sleep study compared to 2nd sleep study (randomised order of intervention/sham or sham/intervention)
Secondary Patient Comfort Patient comfort during the sleep study, as measured by a visual analogue scale (0-10 points). Higher values in the scale range represent a better outcome. 1st sleep study compared to 2nd sleep study (randomised order of intervention/sham or sham/intervention)
Secondary Device Acceptance Device acceptance during sleep study, as measured by a visual analogue scale (0-10points). Higher values in the scale range represent a better outcome. 1st sleep study compared to 2nd sleep study (randomised order of intervention/sham or sham/intervention)
Secondary Sleepiness Daytime sleepiness as an ad-hoc measurement, as measured by the Stanford Sleepiness Scale (0-7 points, x). Higher values in the scale range represent more severe sleepiness. 1st sleep study compared to 2nd sleep study (randomised order of intervention/sham or sham/intervention)
See also
  Status Clinical Trial Phase
Completed NCT01620554 - Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) Phase 2
Not yet recruiting NCT01985347 - The SAD Study - SLEEP, ANXIETY & DEPRESSION Study A Prospective Cohort Study N/A
Completed NCT01312558 - The Effect of the Mediterranean Diet on Obstructive Sleep Apnoea-Hypopnoea Syndrome: A Randomised Trial N/A
Completed NCT02967536 - Investigating the Neuropathology of Obstructive Sleep Apnoea
Completed NCT02855515 - Drug-Induced Sleep Endoscopy for the Optimisation of Treatment of Patients With Obstruction Sleep Apnoea N/A
Terminated NCT03127800 - Morphine in Moderate Obstructive Sleep Apnoea Phase 3
Recruiting NCT04262986 - A Brief Lifestyle Modification Programme in Overweight Subjects With Obstructive Sleep Apnoea - Needs Assessment
Completed NCT03145129 - PAIR Study-PAP And IOP Relationship: Study 2
Completed NCT06376305 - EndoBarrier in Obstructive Sleep Apnoea Study N/A
Completed NCT02713152 - Prevalence of Obstructive Sleep Apnoea in Glaucoma N/A
Terminated NCT01530451 - Clinical Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients Phase 3
Completed NCT02518633 - Obstructive Sleep Apnoea and Adipose Tissue Dysfunction N/A
Completed NCT01557166 - Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALEā„¢ - Sleep Apnoea Phase 3
Recruiting NCT01829854 - To Investigate the Incidence of Obstructive Sleep Apnoea in Patient Undergoing Open Heart Surgery N/A
Completed NCT01619748 - Peripheral Vascular Function in Obstructive Sleep Apnoea N/A
Completed NCT02417584 - Efficacy of PAP Therapy on Blood Pressure N/A
Completed NCT04071860 - Developing a Non-contact Sleep Apnoea Detector, Suitable for Home Studies- The Safescan Study
Not yet recruiting NCT04607343 - Clinical Trial of a Rehabilitation Device Based on Electrostimulation for Obstructive Sleep Apnoea N/A
Completed NCT01546792 - Lifestyle Intervention in Obstructive Sleep Apnoea Phase 2/Phase 3
Completed NCT00300599 - Effect of Continuous Positive Airway Pressure (CPAP) on Systemic Blood Pressure, Coagulability and Carotid Intima-media Thickness in Patients With Sleep Apnea N/A